Lengsin is an eye lens protein with a glutamine synthetase domain. We previously identified this protein as a lung carcinoma antigen through cDNA microarray analysis. Lengsin protein is overexpressed irrespective of the histological type of lung carcinoma, but not in normal tissues other than the lens. Therefore, to significantly extend the use of Lengsinbased T-cell immunotherapies for the treatment of patients with lung carcinoma, we searched for HLA-A * 0201-restricted epitopes from this protein by screening predicted Lengsin-derived candidate peptides for the induction of tumor-reactive CTLs. Four Lengsin-derived peptides were selected by computerized algorithm based on a permissive HLA-A * 0201 binding motif, and were used to immunize HLA-A * 0201 transgenic (HHD) mice. Two of the immunizing peptides, Lengsin(206-215)(FIYDFCIFGV) and Lengsin(270-279)(FLPEFGISSA), induced peptide-specific cytotoxic T lymphocytes (CTLs) in HHD mice, and thus were used to stimulate human peripheral blood lymphocytes in vitro. and Lengsin (270-279) also induced human peptide-specific CTLs, and we were able to generate 
Introduction
Lung cancer is the leading cause of cancer death in the world (1) . Current chemotherapy and radiotherapy regimens provide a limited survival benefit and are often toxic as well as ineffective. Tumor antigen-specific T-cell immunotherapy is a promising new approach to cancer treatment that is more effective and less toxic. Recent studies have shown that the adoptive transfer of normal peripheral lymphocytes genetically modified by the insertion of tumor-reactive T-cell receptors (TCRs) can mediate in vivo complete regression in patients with metastatic melanoma (2, 3) , and synovial cell sarcoma (4) . Identification of naturally presented peptides derived from tumor-associated antigens on the surface of tumor cells, which can induce peptide-specific and tumor-reactive cytotoxic CD8 + T cells (CTLs), is required for antigen-specific T-cell immunotherapy including TCR gene transfer therapy as the therapeutic target. To date, many immunogenic CTL epitopes in the context of HLA-A * 0201, which is the predominant subtype in most ethnic groups (5) , have been identified by reverse immunology approach (6) (7) (8) . In addition, H-2D b-/-, β 2 m -/-, HLA-A * 0201 monochain transgenic (HHD) mouse is a useful animal model for assessing the ability of individual peptides to induce HLA-A * 0201-restricted CTL response (9) (10) (11) (12) (13) (14) (15) . Previously, we used genome-wide cDNA microarray analysis to identify a novel lung cancer antigen, Lengsin, as a potential target for immunotherapy (16) . Lengsin protein is overexpressed irrespective of the histological type of lung carcinoma, but not in normal tissues other than the lens. Because the eye lens is an immune-privileged site (17, 18) , similar to the case of the testis, Lengsin can be an attractive target for tumor antigen-specific immunotherapy, as with cancer-testis antigens.
In the current study, we attempted to identify Lengsinderived CTL epitope via a reverse immunology approach. We studied four Lengsin-derived peptides with the HLA-A * 0201 binding motif selected by HLA-peptide binding predictions of the Bioinformatics and Molecular Analysis Section (BIMAS) program and evaluated their ability to provoke peptide-specific CTL responses in HLA-A * 0201 transgenic (HHD) mice, and then we induced and generated peptide-specific CTL clones from peripheral blood lymphocytes of HLA-A 
Materials and methods
Animals. HLA-A * 0201-transgenic HHD mice were described previously (9) . H-2D b-/-β 2 m -/-double knockout mice introduced with human β 2 m-HLA-A2.1 (α1α2)-H-2D b (α3 transmembrane cytoplasmic) (HHD) monochain construct gene were generated at the Département SIDA-Rétrovirus, Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, France and kindly provided by Dr F.A. Lemonnier. The mice were kept under specific pathogen-free conditions. Mouse experiments were approved by the Animal Research Committee of National Cancer Center Hospital East.
Peptides and plasmids. Human Lengsin-derived peptides (purity >90%) sharing the amino acid sequences with mouse Lengsin and carrying binding motifs for HLA-A * 0201-encoded molecules, were identified using HLA-peptide binding predictions of the Bioinformatics and Molecular Analysis Section (BIMAS) program (http://bismas.dcrt.nih.gov/molbio/hla_ bind/index.html). We purchased a total of four Lengsin-derived peptides carrying HLA-A * 0201 binding motifs (Table I) from GeneWorld (Tokyo, Japan). HIV-gag (77-85)(SLYNTYATL) peptide was used as an irrelevant peptide in murine and human CTL assays. Full-length Lengsin cDNA was obtained from a human lung carcinoma cell line and subcloned into pcDNA3.1 vector (Invitrogen) as described previously (16 ® HD (Roche Applied Science). 1-87-A0201 and SK-Hep-1-Lengsin was cultured in DMEM supplemented with 10% heat-inactivated FBS containing 1 µg/ml puromycin (Sigma-Aldrich) and 1 mg/ml G418 (Gibco), respectively. In addition, COS-7 cells transiently expressing HLA-A * 0201 and/ or full-length Lengsin as the target cells were generated by cotransfection with pCDNA3.1 vector encoding these proteins using Lipofectamine ™ 2000 (Invitrogen).
HLA-A * 0201-binding assay. To determine the binding ability of the predicted peptides to HLA-A * 0201 molecules, an in vitro cellular binding assay was performed as previously reported (20) . Briefly, after incubation of T2 cells in culture medium at 26˚C for 18 h, cells (2x10 5 ) were washed with PBS and suspended in 1 ml of Opti-MEM ® (Invitrogen) with or without 100 µg of peptide, followed by incubation at 26˚C for 3 h and then at 37˚C for 3 h. After washing with PBS, HLA-A * 0201 expression was measured by flow cytometry using FITCconjugated HLA-A2-specific monoclonal antibody (mAb) (BB7.2; BioLegend), and mean fluorescence intensity (MFI) was recorded. Percent MFI increase was calculated as follows: Percent MFI increase = (MFI with the given peptide -MFI without peptide)/(MFI without peptide) x 100.
Induction of Lengsin-derived peptide-specific CTLs in HHD mice. In vivo immunization of mice and in vitro stimulation of primed spleen cells were performed as previously described (12) . Briefly, bone marrow (BM) cells (2x10 6 ) from HHD mice were cultured in RPMI-1640 supplemented with 10% FBS, together with granulocyte macrophage colony-stimulating factor (5 ng/ml) and 2-ME (0.8 ng/ml) for 7 days in 10-cm plastic dishes, and these bone-marrow-derived dendritic cells (BM-DCs) were pulsed with a mixture of the four Lengsinderived peptides carrying HLA-A * 0201 binding motifs (1 µM for each peptide) at 37˚C for 2 h. We primed the HHD mice with this syngeneic BM-DC vaccine (5x10 5 /mouse) into the peritoneal cavity once a week for two weeks. Seven days after the last immunization, the spleens were collected and CD4-negative spleen cells were isolated by negative selection with anti-CD4 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) to exclude any non-specific IFN-γ production by CD4 + spleen cells cocultured with the BM-DCs. The CD4-negative spleen cells (2x10 6 /well) were restimulated with syngeneic BM-DCs (2x10 5 /well) pulsed once with the mixture of peptides in vitro. Six days later, the frequency of cells producing IFN-γ/1x10 5 CD4-negative spleen cells upon stimulation with syngeneic BM-DCs (5x10 4 /well) pulsed with each peptide or the irrelevant peptide, was evaluated in an enzymelinked immunospot (ELISPOT) assay as described below.
Generation of Lengsin peptide-specific CD8
+ T cell clones from human PBMCs. This study was approved by the Ethics Committee of the National Cancer Center, and conforms to the ethical guidelines of the Declaration of Helsinki (1995). CTL clones were generated using the methods described previously with some modifications (21) . Blood samples were collected from HLA-A * 0201 + healthy donors, after informed consent was obtained. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Paque (GE Healthcare) density gradient centrifugation. PBMCs were cultured (5x10 6 cells/well) with 1 or 0.1 µg/ml Lengsin-derived peptide in AIM-V ® medium supplemented with 10% human AB serum, 10 U/ml recombinant human interleukin (rhIL)-2 (Chiron, Emeryville, CA, USA) once a week for two or three weeks and supplemented with 10 U/ml rhIL-2 between stimulations. Seven days after the last stimulation, CD8 + T cells were isolated using a CD8 T-cell isolation kit (Miltenyi Biotec) and plated at 3, 1 and 0.3 cells/well in 96-well round-bottom plates with 5 µg/ml PHA-P (Wako, Tokyo, Japan), 200 U/ml rhIL-2 and 8x10 4 cells/well allogeneic irradiated (100 Gy) PBMCs. Proliferating T cell clones were screened for peptide-specific IFN-γ production by ELISPOT assay using T2 cells pulsed with or without the immunizing peptide.
Enzyme-linked immunosorbent spot (ELISPOT) assay.
Specific IFN-γ secretion of murine and human CTLs in response to stimulator cells was assayed using the IFN-γ ELISPOT Kit (BD Biosciences) according to the manufacturer's instructions. Stimulator cells were pulsed with or without peptide for 1 h at 37˚C and then washed thrice. Responder cells (5x10 4 /well) were incubated with stimulator cells for 20 h. In blocking experiments, peptide-pulsed T2 or tumor cells were preincubated with HLA-A2-specific mAb (BB7.2) or isotype control mAb (mIgG2b; BioLegend) for 1 h. The resulting spots were counted using an ELIPHOTO counter (Minerva Tech, Tokyo, Japan).
Cytotoxicity assay. To measure cytolytic activity of the CTL clones, calcein AM release-based cytotoxic cell assay was performed as described previously (22, 23) . Briefly, 2x10
6 target cells were labeled with green fluorescent probe calcein AM at 37˚C for 30 min and washed thrice. Target cells were pulsed with or without peptide for 1 h at 37˚C and washed thrice. Effector cells were incubated with 1x10 4 target cells for 4 h at the indicated effector-to-target (E:T) ratios. The fluorescence emitted by target cells was measured using a Terascan system (Minerva Tech, Tokyo, Japan) before and after coincubation with effector cells. Percentage of specific lysis was determined as: (experimental release -spontaneous release)/(maximal release -spontaneous release) x 100.
Results

Identification of Lengsin-derived peptide binding to
HLA-A * 0201 molecules. As the candidates of HLA-A * 0201-restricted and human Lengsin-derived CTL epitopes, we selected four peptides having high predicted HLA-A * 0201-binding scores calculated using the BIMAS software program, and we evaluated their binding ability to HLA-A * 0201 molecules (Table I ). All four peptides were able to bind to HLA-A * 0201 molecules. (Fig. 1) . Similar results were obtained in three independent experiments. These results suggest that Lengsin(206-215) and Lengsin(270-279) have immunogenic potential and are able to induce peptide-specific CTLs in HHD mice.
Induction of CTL response against the
Generation of Lengsin-peptide-specific CTL clones from human PBMCs. Next, we assessed the capacity of Lengsin(206- (Fig. 2A) . These three CTL clones had a CD3 + CD8 + CD4 -phenotype determined by flow cytometric analysis (data not shown). In addition, IFN-γ production of CTL clones against cognate peptide-pulsed T2 was inhibited by HLA-A2-specific mAb, but not isotype control mAb, indicating that recognition by these CTL clones was HLA-A2 restricted (Fig. 2B) . Moreover, we evaluated the cytolytic activity of these CTL clones against cognate peptide-pulsed T2 cells (Fig. 2C) . Lengsin (Fig. 4) . Specific IFN-γ production of Lengsin(270-279)-specific CTL clones 1A1 and 1G12 was detectable against COS-7 cells expressing both HLA-A * 0201 and Lengsin, but not the non-treated, and only HLA-A * 0201 or Lengsin-cDNA-transfected COS-7 cells in the absence of cognate peptide. In contrast, IFN-γ production of Lengsin(206-215)-specific CTL clone 3C9 was not detectable against COS-7 cells expressing both HLA-A * 0201 and Lengsin in the absence of cognate peptide (Fig. 4A) . (Fig. 4B) . The specific IFN-γ production was blocked by HLA-A2-specific mAb, but not the isotype control, suggesting that the observed production was HLA-A2 restricted (Fig. 4C) . In contrast, IFN-γ production of Lengsin(206-215)-specific CTL clone 3C9 was not detectable against SK-Hep-1-Lengsin in the absence of cognate peptide (Fig. 4B) (Fig. 5A ). The specific IFN-γ production was blocked by HLA-A2-specific mAb but not the isotype control mAb, suggesting that the observed IFN-γ production was HLA-A2 restricted (Fig. 5B) . In addition, Lengsin(270-279)-specific CTL clone 1G12 was able to specifically lyse 1-87-A0201 (HLA-A * 0201 + / Lengsin + ) (Fig. 5C ). In contrast, Lengsin(206-215)-specific CTL clone 3C9 was unable to recognize and lyse 1-87-A0201 (HLA-A * 0201 + /Lengsin + ) in the absence of cognate peptide ( Fig. 5A and C) . These results suggest that the Lengsin(270-279)-specific CTL clone can recognize the HLA-A * 0201 + lung carcinoma cell line endogenously expressing Lengsin in an HLA-A * 0201-restricted fashion; therefore, Lengsin(270-279) is naturally processed and presented by HLA-A * 0201 molecules on the surface of lung carcinoma cells expressing Lengsin.
Discussion
In order to demonstrate that predicted candidate peptides are naturally presented peptides on tumor cells, it is necessary that CTLs induced by reverse immunology approaches often fail to recognize HLA-matched tumor targets expressing specific genes (24) (25) (26) (27) . Possible explanations with respect to each factor of the induced CTLs and the targeted tumor cells seem plausible.
With regard to the factor of induced CTLs, they might not have sufficient avidity to recognize a limited number of naturally presented peptides on the surface of tumor cells (28) (29) (30) . Consequently, it is necessary to induce high-avidity tumorreactive CTLs. Reported methods for inducing high-avidity CTLs include stimulation with low concentration of peptides (31, 32) , with three costimulatory molecules (B7-1, ICAM-1 and LFA-3) (33), cultured with IL-12 (34) or IL-15 (35) , and using allogeneic PBMCs as a source of CTLs (36) (37) (38) . Additionally, it is very important to demonstrate recognition of tumor cells by CTL clones but not bulk CTL populations in terms of specificity. The bulk CTL populations that were used may have contained distinct CTL clones, some of which were responsible for peptide recognition and others that accounted for the apparent tumor reactivity (39) . In fact, it has been reported that hTERT(540-548) is controversial as to its status as a naturally processed and presented peptide due to different results depending on assessment of bulk CTL populations (11, 40) or CTL clones (41) (42) (43) . Therefore, it is also important to establish highly avid tumor-reactive CTL clones for evaluation of specific tumor reactivity of CTLs. Melanoma-associated antigen-specific high-avidity tumor-reactive CTL clones have been generated by CD107a-guided sorting (44) . In our laboratory, we recently generated GPC3(144-152)-specific high-avidity tumor-reactive CTL clones by CD107a-guided sorting from PBMCs of patients vaccinated with GPC3(144-152) peptide (45) . In this study, we evaluated tumor reactivity using CTL clones, but not bulk CTL populations. Lengsin(206-215)-specific high-avidity tumor-reactive CTL clones could possibly be induced and generated by further studies using the above methods.
With regard to the factor of targeted tumor cells, the predicted candidate peptides might not be processed and presented on the surface of tumor cells. In this study, Lengsin(206-215)-specific CTL clone 3C9 and Lengsin(270-279)-specific CTL clone 1A1 showed approximately similar avidity in peptide titration experiments. CTL clone 1A1 recognized target cells expressing Lengsin; however, CTL clone 3C9 failed. For this reason, Lengsin(206-215) might not be processed and presented on target cells. Peptides presented by MHC class I molecules are usually derived from intracellular proteins that are degraded by the proteasome (46) . In contrast, by using the proteasome inhibitor lactacystin, it has happened that the expression of naturally processed peptide is sharply increased by a proteasome-independent mechanism, resulting in enhanced recognition by CTL clones (25, (47) (48) (49) . It would be interesting to examine whether Lengsin(206-215)-or Lengsin(270-279)-specific CTL clones recognize proteasome inhibitor-treated tumor cells.
As a CTL-independent approach, tandem mass spectrometry (MS) can provide direct identification of naturally presented peptides eluted from MHC class I molecules (50) (51) (52) . Using tandem MS analysis, we can positively demonstrate whether Lengsin(206-215) or Lengsin(270-279) are naturally presented peptides on the surface of tumor cells. In addition, a new presented peptide derived from Lengsin might be detected.
